654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors
654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors
PDF